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Background: A subset of patients with hepatocellular carcinoma (HCC) present with massive tumours.
It is unknown why certain patients develop these massive tumours, and whether this presentation is
specific to the underlying viral aetiology or patient demographics such as gender, race and age.
Methods: All patients with HCC at Bellevue Hospital Center, New York from 1998 to 2012 were identified
and relevant demographic and clinical information was collected. Computed tomography/magnetic
resonance imaging (CT/MRI) images were reviewed and the maximal tumour diameter on axial sections
was recorded. Cirrhosis was defined histologically or by radiographical criteria. The two cohorts of
massive and non-massive HCC were compared.
Results: A total of 361 patients with HCC were identified, of which 58 were categorized as having a
massive HCC using a 13 cm size cut-off. Univariate and multivariate analysis demonstrated a significant
association of massive HCC with age <40 years; hepatitis B or Asian ethnicity; and a lack of cirrhosis or
platelet count >100.
Discussion: Massive HCC represents a tumour subtype that is associated with young, chronic hepatitis
B carriers with non-cirrhotic livers. The clinical implications of this finding are that patients with massive
HCC are typically excellent resection candidates barring the presence of gross vascular invasion or
distant metastases.
Received 23 April 2012; accepted 16 May 2012
Correspondence
Umut Sarpel, Department of Surgery, Mount Sinai School of Medicine, 19 East 98th St, 7th Fl, Ste A,
Box 1259, New York, NY 10029, USA. Tel: +1 212 241 2891. Fax: +1 212 241 1572. E-mail:
umut.sarpel@mountsinai.org
Background
In the United States and Europe, hepatocellular carcinoma (HCC)
is almost always a consequence of cirrhosis, most frequently as a
result of hepatitis C infection (HCV).1 Carcinogenesis occurs as a
result of chronic hepatocyte injury, leading to inflammation, cell-
regeneration and eventual dysplasia. By the time HCC develops,
patients frequently have portal hypertension and poor hepatic
function, severely limiting treatment options.2
By contrast, in most of Asia and sub-Saharan Africa, HCC is
generally as a result of infection with the hepatitis B virus (HBV).1
As a DNA virus, hepatitis B is thought to induce carcinogenesis by
viral integration into the hepatocyte genome leading to viral
promoter-driven transcriptional up-regulation, and induction of
genomic instability.3 As a result, patients with chronic HBV infec-
tion can develop HCC in the absence of cirrhosis.4 Furthermore,
patients from these regions generally develop HCC much earlier,
since the HBV infection occurs perinatally, and thus the hepatic
insult begins at a younger age.4
On imaging, HCC and can vary greatly in its size at presenta-
tion and in its rate of growth. Tumour size is an important factor
for treatment decisions. For example, a size greater than 5 cm
disqualifies a patient from liver transplantation5 and makes abla-
tive treatments less effective.2 A large size also renders transarterial
chemoembolization ineffective, since massive tumours usually
parasitize their blood supply from several sites in addition to the
hepatic artery. While the efficacy of sorafenib has not been
specifically tested in patients with massive HCC, there is
some hesitancy that its use in such large tumours can induce
tumour necrosis and rupture. Therefore, hepatic resection
remains the only treatment for HCC for which there is no strict
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size restriction, although large tumours can clearly make surgery
more challenging owing to their mass effect.
A subset of patients with HCC present with markedly large
tumours which can exceed 25 cm in diameter (Fig. 1). It is
unknown why certain patients develop these massive tumours,
and whether this presentation is specific to the underlying viral
aetiology or patient demographics such as gender, race and age.
The present study describes the demographic and clinical features
associated with massive tumours in hepatocellular carcinoma.
The inverse relationship between cirrhosis and these massive
tumours is noted, and the treatment options and outcomes for
these patients are reviewed.
Methods
After obtaining Institutional Review Board approval, billing and
diagnostic codes were used to identify all patients with HCC at
Bellevue Hospital Center in New York City from January 1998 to
January 2012. A retrospective chart review was then performed. A
diagnosis of HCC was confirmed by either histology or estab-
lished radiological criteria of arterial enhancement and venous
washout.2 Associated socio-demographic data were collected,
including age, gender and race/ethnicity. Race/ethnicity was deter-
mined using either self-declared ethnicity or documentation by
the healthcare provider, as indicated in the electronic medical
records.
Baseline laboratory values recorded upon diagnosis included
total bilirubin, platelets, international normalized ratio (INR),
creatinine and albumin. The presence of underlying liver disease
was noted, including HBV, HCV, alcohol abuse, HIV infection,
diabetes and non-alcoholic fatty liver disease. Hepatitis B diagno-
sis was determined by positive serology results for HBV-surface
antigen or core antibody. Regular alcohol use (i.e. more than one
drink per day) was considered significant.
All computed tomography (CT) or magnetic resonance
imaging (MRI) images were reviewed by one investigator (D.A.),
and the results independently confirmed by a single hepatobiliary
surgeon (U.S.). Cirrhosis was defined either histologically or using
radiographical criteria (i.e. nodularity or other changes in liver
morphology, splenomegaly, the presence of varices or ascites). The
maximal tumour diameter on axial sections was recorded as a
simple surrogate for tumour volume. Gross vascular invasion,
tumour number, and/or distant metastases were noted.
Method of treatment was recorded, including resection, trans-
plantation, chemoembolization, ablation, sorafenib and other
modalities. In patients who underwent a resection, the histological
appearance of the tumour was examined.
Statistical analysis was performed using SPSS version 17.0 and
R package (R Development Core Team).6 Reports in the literature
suggested that massive tumours tended to occur in patients
without cirrhosis.7,8 This was investigated by plotting the distri-
bution of tumour size by the presence or absence of cirrhosis, and
demonstrated that the majority of tumours in cirrhotic patients
were smaller than 10 cm (Fig. 2). A preliminary chi-square test
was performed using 10 cm as a cut-off, suggested by previous
publications on massive tumours.8 This confirmed that the inci-
dence of cirrhosis was significantly less in patients with tumours
smaller than 10 cm in size (P < 0.05). To more accurately define
the tumour size at which point the association with hepatic cir-
rhosis became significant, serial tumour size cut-offs were used to
create dichotomized groups. Chi-square tests were used to
compare the incidence of cirrhosis for each cut-off. The value
corresponding to the statistically significant divergence in rates of
cirrhosis resulted in a definition of ‘massive HCC’ as 13 cm.
This size corresponded well to the size cut-off seen with the other
clinical and demographic features known to be associated with a
lack of cirrhosis, e.g. young age, platelets >100 000, hepatitis B
and Asian ethnicity4 (Fig. 3). Using this resulting definition of
13 cm, the two cohorts of massive and non-massive HCC were
compared. Univariate analysis was conducted using chi-square
tests for categorical variables, and Mann–Whitney U-tests for
non-parametric continuous variables. Normality was examined
using quantile–quantile plots and the Kruskal-Wallis test.
Logistic regression multivariate analysis was conducted in the
standard fashion using variables that were clinically important
base on a priori knowledge.Multivariate models were constructed
with independent variables that were not associated with each
other.
Survival was measured in months from the date of HCC diag-
nosis. Death was confirmed by the Social Security Death Index or
our institutional Tumor Registry. As a result of the small number
of patients with massive HCC undergoing resection, survival was
dichotomized as survival >1 year, and survival >2 years. Fisher’s
exact test was used to compare rates between the massive and
non-massive cohorts.
Figure 1 Massive hepatocellular carcinoma (HCC) in a non-cirrhotic
liver
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Figure 2 Weighted plot of tumour size distribution by the presence or absence of cirrhosis
Figure 3 A plot of P-values derived from chi-square tests comparing various cut-offs for tumour size and the presence of cirrhosis, age,
hepatitis B, Asian race/ethnicity and thrombocytopenia, demonstrating a divergence in significance above 13 cm
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Results
A total of 361 patients with HCC were identified (Table 1). The
mean age at HCC diagnosis was 55 years [standard deviation (SD)
 13]. Eighty-three per cent (n = 300) were male. In 355 patients,
information on ethnicity was available. Patients defined them-
selves as Asian (48%) Hispanic (25%), African American (18%),
Caucasian (3%) or other (4%).
Aetiology of the underlying liver disease was defined as HBV in
52% (n = 187/361), HCV in 35% (n = 125/361) alcohol without
HCV in 3%, diabetes or non-alcoholic fatty liver disease in 3%,
multiple aetiologies in 4%, and in 4% (n = 13) of patients no
identifiable aetiology was documented. In the 307 patients where
information on symptoms was available, 45% of patients (n =
163/307) were asymptomatic at diagnosis, 35% (n = 126/307)
complained of abdominal pain, 2% (n = 8/307) presented with
weight loss, 1% (n = 2/307) presented with jaundice, and 2% (n =
8/307) had other complaints which led to abdominal imaging.
At diagnosis, the median tumour size was 4.7 cmwith a positive
skew, and ranged from 1.0 to 24.9 cm. Unifocal tumours were
present in 193 patients (53%), 61 patients (17%) had two
tumours, 14 patients had three tumours (4%) and 93 patients
(26%) had greater than three tumours present at diagnosis. Gross
vascular invasion into the portal or hepatic veins was present in 89
patients (24.7%) at the time of diagnosis. Using the Child–Pugh
scoring system to assess liver function, 254 patients (72%) were
class A, 87 patients (25%) were class B and 13 patients (4%) were
class C.
Using the definition of 13 cm obtained as described in the
methods, 58 of the 361 patients (16.1%)were categorized as having
massive HCC. Univariate analysis demonstrated significant differ-
ences between these two cohorts, as shown in the Table 1.
Multivariate analysis with logistic regression was performed. To
avoid multicollinearity, Asian race/ethnicity and HBV infection
were not used in the same model as these factors were found to be
associated. Similarly, cirrhosis and thrombocytopenia were not
used in the same model as these factors were also associated.
Logistic regression demonstrated a significant association of
massive HCC with age <40 years [odds ratio (OR) = 0.22, P <
0.001], hepatitis B (OR = 5.8, P < 0.001) or Asian ethnicity (4.5, P
< 0.001), and lack of cirrhosis (OR = 0.22, P < 0.001) or platelet
count >100 (OR = 4.7, P = 0.004).
Treatment modality also differed significantly between the
cohorts, as shown in the Table 1. In looking specifically at the
outcome of all patients who underwent a resection, of the six
patients with massive HCC who underwent a resection, five were
alive at 1 year, and two were alive at 2 years from the date of
diagnosis. This was compared with the 66 patients in the non-
massive group who underwent a resection, of whom 49 (74%)
were alive at 1 year and 39 (59%) who were alive at 2 years. Fisher’s
exact test did not demonstrate any difference in the likelihood of
survival to 1 or 2 years from the date of diagnosis. Resection
specimens were available from three patients with massive HCC.
These specimens were notable for the presence of a pseudocapsule
encompassing the tumour (Fig. 4).
Discussion
The term ‘massive HCC’was first used by Eggel in 1901 to describe
large tumours which replaced much of the entire right or left
hepatic lobe.9 This term was later used by Yuki and colleagues in
Table 1 Features of massive vs. non-massive HCC
Massive
(n = 58)
Non-massive
(n = 303)
P-value
Demographical features
Age 47 years 57 years <0.001
Male gender 51 (88%) 249 (82%) NS
Asian ethnicity 45 (78%) 129 (42%) <0.001
Clinical features
Hepatitis B 48 (83%) 139 (46%) <0.001
Radiologic cirrhosis 16 (29%) 216 (72%) <0.001
Platelets <100 4 (7%) 92 (30%) <0.001
Tumour features
Gross vascular invasion 31 (53%) 58 (19%) <0.001
Extrahepatic metastases 9 (16%) 16 (5%) <0.008
Treatment
No treatment 29 (53%) 105 (35%) <0.001
Sorafenib 13 (24%) 19 (6%)
Chemotherapy 3 (5%) 24 (8%)
Embolization 3 (5%) 47 (16%)
Ablation 0 34 (11%)
Radiation 1 (2%) 0
Transplantation 0 4 (1%)
Resection 6 (11%) 66 (22%)
Figure 4 An example of the tumour pseudocapsule seen with
massive HCC
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1990 to describe tumours which were poorly demarcated from the
surrounding parenchyma.7 While this definition was irrespective
of tumour size, the majority of patients which they categorized as
massive HCC were larger than 10 cm.7 A greater proportion of
patients with massive HCC were younger than 40 years of age and
more often had extrahepatic metastases when compared with
other tumour types – consistent with the current findings.7
In 1993, Trevisani and colleagues reported on patients with
massive HCC, defined by a tumour greater than 10 cm with
poorly demarcated borders, and found a significant association
of massive tumours with non-cirrhotic livers, as confirmed by
the present findings.8More recently, Barazani and colleagues
reported that HBV patients presented with larger maximum
tumour diameters, and more HBV patients had tumours greater
than 5 cm compared with HCV patients.10
The aim of this study was to confirm the inverse relationship
between cirrhosis and massive HCC and to more accurately
describe massive HCC. The present results reveal that patients
with tumours larger than 13 cm can be defined as having massive
HCC and that this tumour subtype is associated with young,
chronic hepatitis B carriers with non-cirrhotic livers. This number
should not be thought of as a strict size cut-off, but instead reflects
the point at which the clinician can be confident that tumour
characteristics may be different than expected.
The clinical implications of this finding are that patients with
massive HCC are typically excellent resection candidates barring
the presence of gross vascular invasion or distant metastases. In
the current series, only a small number of patients with massive
HCC underwent resection, but the results in these select patients
were reasonable. By comparison, in a report on the natural history
of Chinese patients with large HCC tumours (>5 cm), the median
survival was only 2.7 months.11
The present study was not designed to address the underlying
mechanism of the development of massive HCC. However, the
authors hypothesize that the compliant tissue of the non-cirrhotic
liver may offer less resistance to expansive tumour growth.
In conclusion, patients with HCC tumours greater than 13 cm
in size should be considered as havingmassiveHCC, and should be
evaluated in this context, understanding that their aetiology and
treatment options differ from the majority of patients with HCC.
Massive HCC represents a tumour subtype that is associated with
young, chronic hepatitis B carriers with non-cirrhotic livers. Treat-
ment options are limited in these individuals; however, the absence
of cirrhosis makes them excellent resection candidates when
metastases or prohibitive vascular invasion are not present. It is
critical to aggressively pursue resection in candidate patients, as no
other treatment options exist for tumours of such a large size.
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